Centiva Capital, LP Arvinas, Inc. Transaction History

Centiva Capital, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$36.38 - $52.31 $180,808 - $259,980	4,970 New	4,970 $205,000
Q3 2023 Nov 14, 2023	BUY	$19.64 - $28.21 $230,612 - $331,241	11,742 New	11,742 $230,000
Q2 2021 Aug 16, 2021	SELL	$60.45 - $84.26 $272,629 - $380,012	-4,510 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$58.19 - $91.37 $262,436 - $412,078	4,510 New	4,510 $298,000

229

68.4M

226K

285K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $1.02B
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.